Status:
UNKNOWN
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
Lead Sponsor:
Shanghai YingLi Pharmaceutical Co. Ltd.
Conditions:
Advanced Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing th...
Detailed Description
The trial can be divided into two parts: dose escalation part and dose expansion part. Camrelizumab will be administrated intravenously in a predetermined fixed dose(200mgQ3w）in both parts. In dose ...
Eligibility Criteria
Inclusion
- 18 years old≦age≦75 years old;
- Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumors；
- Failure of previous standard treatment (sufficient prior treatment and no better treatment than participating in clinical research);
- Qualified basic organ function and body condition;
- The expected survival is greater than 3 months;
- Adequate washout period.
Exclusion
- Prior allergy to study drug components;
- Chronic metabolic diseases that are poorly controlled by medication;
- Brain metastases, infection, hemorrhage, autoimmune disease or cardiovascular disease, whichever is in active state;
- Digestive tract diseases that affect absorption of studied drugs.
Key Trial Info
Start Date :
June 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2024
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT05429398
Start Date
June 30 2022
End Date
May 30 2024
Last Update
June 23 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.